Product mix deterioration in acute season
Q2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
medium · management_commentaryAlkem Laboratories Limited — Q1 FY25
Alkem Laboratories reported a strong Q1 FY25 with EBITDA margin expanding 700 bps YoY to 20.1%, driven by favorable API pricing, improved product mix, and cost controls.
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Investment drag from Enzene and medical devices
New initiatives (CDMO, medical devices) will incur losses and impact EBITDA by ~0.5 ppt in H2, with breakeven expected only by FY26.
medium · management_commentaryUS price erosion and launch delays
US generic business faces single-digit price erosion; new product ramp-up may be slower than expected, limiting revenue contribution.
medium · analyst_questionMirabegron launch uncertainty
Launch of Mirabegron is tied to litigation outcomes and settlement agreement, with earliest possible entry in 2026-27, limiting near-term US upside.
low · analyst_question